Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology adds Timothy Coughlin to board, names him audit committee chair

Neutral Impact 3 of 5 leadership Written later

Vir Biotechnology expanded its board from seven to eight members on June 9, 2026, and appointed Timothy Coughlin, CPA, to the new seat and as Chair of the Audit Committee, effective immediately. The change adds a new director to oversee financial reporting and audit matters, and the filing discloses no related party transactions involving him.

Key points

  • Board size increased from seven to eight members; Timothy Coughlin, CPA, appointed as Class III director until the 2028 annual meeting
  • Coughlin named Chair of the Audit Committee, effective immediately
  • As a non-employee director, he receives standard compensation under the company's director policy and automatic option and RSU grants on his appointment date
  • Company has entered into its standard indemnity agreement with him

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECJun 10, 2026, 4:27 PM ET
Accession number0001628280-26-042237

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.